Diffuse large B cell lymphoma overview
|
Diffuse large B cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diffuse large B cell lymphoma overview On the Web |
|
American Roentgen Ray Society Images of Diffuse large B cell lymphoma overview |
|
Directions to Hospitals Treating Diffuse large B cell lymphoma |
|
Risk calculators and risk factors for Diffuse large B cell lymphoma overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on molecular, genetic, and immunohistochemical features into more than 20 subgroups. There are no established causes for diffuse large B cell lymphoma. Diffuse large B cell lymphoma is the most common type of non-Hodgkin lymphoma among adults,[1] with an annual incidence of 7–8 cases per 100,000 people per year.[2][3]This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,[3] though it can also occur in children and young adults in rare cases.[4]The most potent risk factor in the development of diffuse large B cell lymphoma is immunodeficiency. Diffuse large B cell lymphoma must be differentiated from other diseases such as follicular lymphoma, Mucosa-Associated Lymphatic Tissue lymphoma(MALT), Small cell lymphocytic lymphoma, and Mantle cell lymphoma (MCL). The prognosis of diffuse large B cell lymphoma is good with treatment. Diffuse large B cell lymphoma is associated with a 5 year survival rate ranging from 70% to more than 90% among children. According to the Lugano classification, there are four stages of diffuse large B cell lymphoma based on the number of nodes involved and extranodal status. The most common symptoms of diffuse large B cell lymphoma include a rapidly enlarging, non-painful mass that may be located in neck, groin or abdomen. The less common symptoms of diffuse large B cell lymphoma include fever, weight loss and drenching night sweats. Common physical examination findings of diffuse large B cell lymphoma include a non tender mass which can arise in virtually any part of the body. Laboratory tests helpful in the diagnosis of diffuse large B cell lymphoma include complete blood count, LDH, and lymph node biopsy. CT scan is helpful in the diagnosis of diffuse large B cell lymphoma. Lymph node or extranodal tissue biopsy is diagnostic of large B cell lymphoma. Optional procedures include brain MRI, lumbar puncture to analyze cerebrospinal fluid, and CT or PET-CT scans. The optimal therapy for diffuse large B cell lymphoma depends on the stage at diagnosis. The predominant therapy for diffuse large B cell lymphoma is chemotherapy. Adjunctive radiotherapy may be required.
Classification
Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on molecular, genetic, and immunohistochemical features into more than 20 subgroups.
Pathophysiology
Diffuse large B cell lymphoma may be classified into 2 subtypes based on gene expression profiles. The progression to diffuse large B cell lymphoma involves the microRNAs (miRNAs). On microscopic histopathological analysis, diffuse large B cell lymphoma can be divided into three variants: centroblastic, immunoblastic, and anaplastic.
Causes
There are no established causes for diffuse large B cell lymphoma.
Differential diagnosis
Diffuse large B cell lymphoma must be differentiated from other diseases such as follicular lymphoma, Mucosa-Associated Lymphatic Tissue lymphoma(MALT), Small cell lymphocytic lymphoma, and Mantle cell lymphoma (MCL).
Epidemiology and demographics
Diffuse large B cell lymphoma is the most common type of non-Hodgkin lymphoma among adults,[1] with an annual incidence of 7–8 cases per 100,000 people per year.[2][3]This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,[3] though it can also occur in children and young adults in rare cases.[4]
Risk factors
The most potent risk factor in the development of diffuse large B cell lymphoma is immunodeficiency.
Prognosis
The prognosis of diffuse large B cell lymphoma is good with treatment. Diffuse large B cell lymphoma is associated with a 5 year survival rate ranging from 70% to more than 90% among children.
Staging
According to the Lugano classification, there are four stages of diffuse large B cell lymphoma based on the number of nodes involved and extranodal status.
History and symptoms
The most common symptoms of diffuse large B cell lymphoma include a rapidly enlarging, non-painful mass that may be located in neck, groin or abdomen. The less common symptoms of diffuse large B cell lymphoma include fever, weight loss and drenching night sweats.
Physical examination
Common physical examination findings of diffuse large B cell lymphoma include a non tender mass which can arise in virtually any part of the body.
Laboratory tests
Laboratory tests helpful in the diagnosis of diffuse large B cell lymphoma include complete blood count, LDH, and lymph node biopsy
CT
CT scan is helpful in the diagnosis of diffuse large B cell lymphoma.
Biopsy
Lymph node or extranodal tissue biopsy is diagnostic of large B cell lymphoma.
Other diagnostic studies
Optional procedures include brain MRI, lumbar puncture to analyze cerebrospinal fluid, and CT or PET-CT scans.
Medical therapy
The optimal therapy for diffuse large B cell lymphoma depends on the stage at diagnosis. The predominant therapy for diffuse large B cell lymphoma is chemotherapy. Adjunctive radiotherapy may be required.
References
- ↑ 1.0 1.1 "A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project". Blood. 89 (11): 3909–18. 1997. PMID 9166827.
- ↑ 2.0 2.1 Morton, L. M.; Wang, S. S.; Devesa, S. S.; Hartge, P; Weisenburger, D. D.; Linet, M. S. (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–76. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
- ↑ 3.0 3.1 3.2 3.3 Smith, A; Howell, D; Patmore, R; Jack, A; Roman, E (2011). "Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network". British Journal of Cancer. 105 (11): 1684–92. doi:10.1038/bjc.2011.450. PMC 3242607. PMID 22045184.
- ↑ 4.0 4.1 Smith, Alexandra; Roman, Eve; Howell, Debra; Jones, Richard; Patmore, Russell; Jack, Andrew; Haematological Malignancy Research Network (2010). "The Haematological Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research". British Journal of Haematology. 148 (5): 739–53. doi:10.1111/j.1365-2141.2009.08010.x. PMC 3066245. PMID 19958356.